Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.54 USD | +0.05% |
|
-1.01% | -32.06% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.11 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 4.73 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.06% | 5.06B | - | ||
-7.22% | 178B | C+ | ||
-6.72% | 98.53B | C | ||
-7.50% | 65.18B | A | ||
-10.57% | 44.13B | B- | ||
+8.92% | 44.05B | B- | ||
+13.76% | 42.51B | B+ | ||
+9.65% | 28.41B | B | ||
+21.35% | 25.31B | A- | ||
-9.13% | 23.31B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- STVN Stock
- Ratings Stevanato Group S.p.A.